EUVIMEDEUVIMED entdecken
Crossref

Natural Product–Inspired PROTACs for Leukemia Therapy: Hederagenin-Driven Targeted Degradation of SKP2

Lei Chen, Tao Bi, Juan Huang, Bingwen Zhu, Xuemei Yang, Shengdan Yao, Xiyu Dai, Chunyan Liu, Ting Wang, Li Liu, Qin Sun, Jinxiang Wang und 3 weitere

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c03213 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Lei Chen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Environmental Health Effects and Risk Assessment Key Laboratory of Luzhou, School of Public Health, Southwest Medical University, Luzhou 646000, Chin…. Hauptthemen laut MEDLINE: S-Phase Kinase-Associated Proteins, Antineoplastic Agents, Biological Products, Leukemia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Sichuan Provincial Administration of Traditional Chinese Medicine, Sichuan Provincial Science and Technology Support Program, Luzhou Science and Luzhou Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leukemia is a malignant neoplasm originating from the hematopoietic system. T-cell acute lymphoblastic leukemia (T-ALL) represents a typical subtype, posing a particularly serious threat to children. Hederagenin (HED) is a natural product with broad-spectrum antitumor potential, yet its activity remains insufficient and requires optimization. Here, we employed PROTAC technology to design and synthesize a series of HED derivatives. Among them, HD15 demonstrated optimal activity in Jurkat cells (IC50 = 0.98 μM), significantly outperforming the parent compound HED (IC50 > 40 μM), and effectively inhibited xenograft tumor growth. Mechanistically, HD15 effectively degraded SKP2 (DC50 = 0.29 μM), stabilizing SOCS1 expression and modulating immunoproteasome expression via the JAK/STAT pathway, thereby suppressing tumor cell proliferation. The discovery of HD15 demonstrates the promise of PROTAC technology in enhancing the efficacy of natural products and identifying therapeutic targets, offering a novel strategy for developing therapeutics from natural products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

S-Phase Kinase-Associated ProteinsAntineoplastic AgentsBiological ProductsLeukemiaHumansProteolysis Targeting ChimeraAnimalsCell ProliferationMiceJurkat CellsProteolysisStructure-Activity RelationshipCell Line, TumorXenograft Model Antitumor Assays

Substanzen

Proteolysis Targeting ChimeraS-Phase Kinase-Associated ProteinsAntineoplastic AgentsSKP2 protein, humanBiological Products

Autor:innen und Institutionen

  • Environmental Health Effects and Risk Assessment Key Laboratory of Luzhou, School of Public Health, Southwest Medical University, Luzhou 646000, China.
  • State Key Laboratory of Mechanism and Quality of Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and Technology, Macau 999078, China.
  • Drug Research Center of Integrated Traditional Chinese and Western Medicine, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan 646000, China.
  • Guangdong Provincial Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Skin Structure and Function Key Laboratory of Luzhou, Department of Dermatology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan 646000, China.
  • Luzhou Key Laboratory of Research and Development of Medical Institution Preparations and Large-Scale Health Products, Luzhou, Sichuan 646000, China.

ORCID-Profile: Pei Luo, Jun Bai, Zengjin Liu

Förderung

  • Sichuan Provincial Administration of Traditional Chinese Medicine
  • Sichuan Provincial Science and Technology Support Program
  • Luzhou Science and Luzhou Science and Technology Bureau
  • Research Project on the Integration of Traditional Chinese and Western Medicine Conducted at Southwest Medical University
  • Southwest Medical University ?Dual-Campus? Science and Technology Strategic Cooperation Program

Zitieren

APA

Chen, L., Bi, T., Huang, J., Zhu, B., Yang, X., Yao, S., Dai, X., Liu, C., Wang, T., Liu, L., Sun, Q., Wang, J., Luo, P., Bai, J., & Liu, Z. (2026). Natural Product–Inspired PROTACs for Leukemia Therapy: Hederagenin-Driven Targeted Degradation of SKP2. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03213

Vancouver

Chen L, Bi T, Huang J, Zhu B, Yang X, Yao S, et al. Natural Product–Inspired PROTACs for Leukemia Therapy: Hederagenin-Driven Targeted Degradation of SKP2. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03213

BibTeX
@article{Chen2026,
  author = {Chen, Lei and Bi, Tao and Huang, Juan and Zhu, Bingwen and Yang, Xuemei and Yao, Shengdan and Dai, Xiyu and Liu, Chunyan and Wang, Ting and Liu, Li and Sun, Qin and Wang, Jinxiang and Luo, Pei and Bai, Jun and Liu, Zengjin},
  title = {Natural Product–Inspired PROTACs for Leukemia Therapy: Hederagenin-Driven Targeted Degradation of SKP2},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c03213}
}
Kostenlos starten →